Fibromyalgia and Chronic Pain Syndromes: A White Paper Detailing Current Challenges in the Field.

"Editorial support was provided by SuEllen Farrell at Health and Wellness Partners of New Jersey LLC, and was funded by Pfizer Inc., New York, NY. L.M.A.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; she did not receive an honorarium for serving as an author. She currently is a consultant for Pfizer Inc., New York, NY; Daiichi Sankyo, Tokyo, Japan; Forest Laboratories, New York, NY; and Zynerba Pharmaceuticals, Devon, PA; and has received past consultancy fees from Dainippon Sumitomo Pharma, Tokyo, Japan; Innovative Med Concepts LLC (IMC), Tuscaloosa, AL; Ironwood Pharmaceuticals, Cambridge, MA; Purdue Pharma, Stamford, CT; Shire, Lexington, MA; Theravance Biopharma, South San Francisco, CA; and Toray, Tokyo, Japan. She has grants pending with Pfizer Inc., New York, NY; Eli Lilly and Company, Indianapolis, IN; Forest Laboratories, New York, NY; and Tonix Pharmaceuticals, New York, NY (money to institution); and has received past grants from Cerephex Corporation, Los Altos, CA, and Theravance Biopharma, South San Francisco, CA (money to institution). She also has received payment for lectures on behalf of Pfizer Inc., New York, NY. E.C.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. Currently he is receiving consultancy fees and payment for lectures from Pfizer Inc., New York, NY. In addition, he is involved in Pfizer clinical trials for which fees are paid to his institution. D.J.C.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He is a consultant for Tonix Pharmaceuticals, New York, NY; Theravance Biopharma, South San Francisco, CA; Pfizer Inc., New York, NY; Abbott Laboratories, Abbott Park, Illinois; Samumed, San Diego, CA; Merck, Kenilworth, NJ; Eli Lilly and Company, Indianapolis, IN; UCB Pharma, Smyrna, GA; Johnson & Johnson, New Brunswick, NJ; Forest Laboratories, New York, NY; Purdue Pharma, Stamford, CT; and Zynerba Pharmaceuticals, Devon, PA. He has received grants from the National Institutes of Health, Bethesda, MD, and Eli Lilly and Company, Indianapolis, IN, and has several grants pending with the National Institutes of Health. D.L.G.: is a consultant to Pfizer Inc., New York, NY, and received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. R.E.H.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He also has received funding including grants (past; money to institution), consulting fees or honoraria (ongoing), support for travel to meetings (past), and fees for participating in review activities (past) from Pfizer Inc., New York, NY. M.H.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He also has received consultancy fees (past), payment for lectures including service on speakers bureaus (current), and payment for development of educational presentations (current) from Pfizer Inc., New York, NY. T.S.J.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript (money to institution); he did not receive an honorarium for serving as an author. He also has received consultancy fees from Grünenthal, Aachen Germany (ongoing); Orion Pharma, Espoo, Finland (ongoing); and Pfizer Inc., New York, NY (past). K.N.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He received consulting fees or honoraria and support for travel to meetings from Pfizer Inc., New York, NY (past). He also has received consultancy fees (ongoing), grants (ongoing), and speaker fees (past) from Pfizer Japan, Tokyo, Japan. S.L.S.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. In addition, he is receiving board membership fees from Pfizer Inc., New York, NY (current). T.U.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He has received expert testimony fees (past), and grants (ongoing), from Pfizer Inc., New York, NY, and payment for lectures from other pharmaceutical companies. G.W.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He also has received payment for lectures, development of educational presentations, and meeting expenses, and has patents planned, pending, or issued with Pfizer Inc., New York, NY. S.F. has reported no conflicts of interest related to the content of this manuscript."

"Editorial support was provided by SuEllen Farrell at Health and Wellness Partners of New Jersey LLC, and was funded by Pfizer Inc., New York, NY. L.M.A.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; she did not receive an honorarium for serving as an author. She currently is a consultant for Pfizer Inc., New York, NY; Daiichi Sankyo, Tokyo, Japan; Forest Laboratories, New York, NY; and Zynerba Pharmaceuticals, Devon, PA; and has received past consultancy fees from Dainippon Sumitomo Pharma, Tokyo, Japan; Innovative Med Concepts LLC (IMC), Tuscaloosa, AL; Ironwood Pharmaceuticals, Cambridge, MA; Purdue Pharma, Stamford, CT; Shire, Lexington, MA; Theravance Biopharma, South San Francisco, CA; and Toray, Tokyo, Japan. She has grants pending with Pfizer Inc., New York, NY; Eli Lilly and Company, Indianapolis, IN; Forest Laboratories, New York, NY; and Tonix Pharmaceuticals, New York, NY (money to institution); and has received past grants from Cerephex Corporation, Los Altos, CA, and Theravance Biopharma, South San Francisco, CA (money to institution). She also has received payment for lectures on behalf of Pfizer Inc., New York, NY. E.C.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. Currently he is receiving consultancy fees and payment for lectures from Pfizer Inc., New York, NY. In addition, he is involved in Pfizer clinical trials for which fees are paid to his institution. D.J.C.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He is a consultant for Tonix Pharmaceuticals, New York, NY; Theravance Biopharma, South San Francisco, CA; Pfizer Inc., New York, NY; Abbott Laboratories, Abbott Park, Illinois; Samumed, San Diego, CA; Merck, Kenilworth, NJ; Eli Lilly and Company, Indianapolis, IN; UCB Pharma, Smyrna, GA; Johnson & Johnson, New Brunswick, NJ; Forest Laboratories, New York, NY; Purdue Pharma, Stamford, CT; and Zynerba Pharmaceuticals, Devon, PA. He has received grants from the National Institutes of Health, Bethesda, MD, and Eli Lilly and Company, Indianapolis, IN, and has several grants pending with the National Institutes of Health. D.L.G.: is a consultant to Pfizer Inc., New York, NY, and received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. R.E.H.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He also has received funding including grants (past; money to institution), consulting fees or honoraria (ongoing), support for travel to meetings (past), and fees for participating in review activities (past) from Pfizer Inc., New York, NY. M.H.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He also has received consultancy fees (past), payment for lectures including service on speakers bureaus (current), and payment for development of educational presentations (current) from Pfizer Inc., New York, NY. T.S.J.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript (money to institution); he did not receive an honorarium for serving as an author. He also has received consultancy fees from Grünenthal, Aachen Germany (ongoing); Orion Pharma, Espoo, Finland (ongoing); and Pfizer Inc., New York, NY (past). K.N.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He received consulting fees or honoraria and support for travel to meetings from Pfizer Inc., New York, NY (past). He also has received consultancy fees (ongoing), grants (ongoing), and speaker fees (past) from Pfizer Japan, Tokyo, Japan. S.L.S.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. In addition, he is receiving board membership fees from Pfizer Inc., New York, NY (current). T.U.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He has received expert testimony fees (past), and grants (ongoing), from Pfizer Inc., New York, NY, and payment for lectures from other pharmaceutical companies. G.W.: received an honorarium and support for travel to a meeting to discuss the development of this manuscript; he did not receive an honorarium for serving as an author. He also has received payment for lectures, development of educational presentations, and meeting expenses, and has patents planned, pending, or issued with Pfizer Inc., New York, NY. S.F. has reported no conflicts of interest related to the content of this manuscript."